Based on baseline characteristics, patients treated with anti‐PD‐1 monoclonal antibodies in the present cohort had lower tumour burden (expressed as initial serum LDH level and the number of involved organs), and the present study population consisted of exclusively BRAF‐mutated patients. This evidence concerns the gene BRAF and neoplasm.